Currently out of the existing stock ratings of Kostas Biliouris, 8 are a HOLD (25%), 24 are a BUY (75%).

Kostas Biliouris

Work Performance Price Targets & Ratings Chart

Analyst Kostas Biliouris, currently employed at BMO, carries an average stock price target met ratio of 32.58% that have a potential upside of 46.58% achieved within 87 days.

Kostas Biliouris’s has documented 69 price targets and ratings displayed on 11 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CNTA, Centessa Pharmaceuticals PLC ADR at 16-Sep-2024.

Wall Street Analyst Kostas Biliouris

Analyst best performing recommendations are on BEAM (BEAM THERAPEUTICS ).
The best stock recommendation documented was for BEAM (BEAM THERAPEUTICS ) at 7/18/2022. The price target of $61 was fulfilled within 1 day with a profit of $2.99 (5.15%) receiving and performance score of 51.54.

Average potential price target upside

BEAM Beam Therapeutics  CNTA Centessa Pharmaceuticals PLC ADR CRSP Crispr Therapeutics AG DTIL Precision BioSciences GRPH Graphite Bio LEGN Legend Biotech Corp NTLA Intellia Therapeutics VERV Verve Therapeutics BMRN Biomarin Pharmaceutical ALNY Alnylam Pharmaceuticals FDMT 4D Molecular Therapeutics 

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$39

$14.95 (62.16%)

$32

14 days ago
(06-Nov-2024)

1/10 (10%)

$12.36 (46.40%)

118

Hold

$24

$-0.05 (-0.21%)

$27

14 days ago
(06-Nov-2024)

5/6 (83.33%)

$-2.64 (-9.91%)

83

Hold

$24

$-0.05 (-0.21%)

$35

1 months 4 days ago
(16-Oct-2024)

2/4 (50%)

$-2.69 (-10.08%)

38

Buy

$69

$44.95 (186.90%)

$66

2 months 9 days ago
(11-Sep-2024)

0/3 (0%)

$44.88 (186.07%)

Buy

$48

$23.95 (99.58%)

$40

3 months 13 days ago
(07-Aug-2024)

3/6 (50%)

$23.54 (96.24%)

237

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Kostas Biliouris is most bullish on?

Potential upside of $31.17 has been obtained for FDMT (4D MOLECULAR THERAPEUTICS )

Which stock is Kostas Biliouris is most reserved on?

Potential downside of -$9.26 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

What Year was the first public recommendation made by Kostas Biliouris?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?